Barclays began coverage of U.S. large-cap biopharma with a Neutral industry view and designated Eli Lilly, Merck, Bristol-Myers Squibb and AbbVie as its preferred picks, notably leaving Pfizer off its top-four list. The global GLP-1 segment is forecast to grow at an 8.6% CAGR to $33.26 billion by 2030, driven by oral formulation innovations and long-acting peptides, positioning Pfizer to capture incremental diabetes and obesity treatment sales. The sexual health supplement industry is projected to rise from $3.79 billion in 2026 to $5.31 billion by 2030 at an 8.8% CAGR, with Pfizer among leading firms set to benefit from personalized formulations and e-commerce distribution growth.